Glaukos (NYSE:GKOS) Releases Quarterly Earnings Results

Glaukos (NYSE:GKOS) announced its quarterly earnings data on Thursday. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%.

Glaukos Stock Down 1.6 %

NYSE:GKOS traded down $2.61 during trading hours on Thursday, hitting $157.97. The stock had a trading volume of 1,064,575 shares, compared to its average volume of 568,425. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos has a 1-year low of $83.90 and a 1-year high of $163.71. The business has a 50 day simple moving average of $152.65 and a two-hundred day simple moving average of $139.03. The company has a market cap of $8.71 billion, a PE ratio of -52.31 and a beta of 1.04.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Truist Financial increased their price objective on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $140.00 to $200.00 in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective (up from $140.00) on shares of Glaukos in a report on Monday, January 27th. Stifel Nicolaus increased their price objective on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Finally, BTIG Research increased their price objective on shares of Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $159.42.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 over the last 90 days. 6.40% of the stock is owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.